Clinical trials: Cardiovascular Event
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Atherosclerosis, Cardiovascular Diseases
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- Trial name
- ACCLAIM-CTA (NCT07613294)
- Testing
- Lepodisiran
- Where
- 58 sites in United States, Australia and 5 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation, Cardiovascular Disease
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
The purpose of this study was to determine if Irbesartan compared to Placebo would reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death in patients with Atrial Fibrillation…
- Trial name
- ACTIVE I (NCT00249795)
- Testing
- Irbesartan
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 9,016 people
- Sponsor
- Sanofi
Upper Limb Spasticity
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT05956509
- Testing
- ABBV-950, BOTOX
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie
Acute Coronary Syndrome
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).
- Trial name
- NCT00548587
- Testing
- E5555
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Eisai Inc.
Hyperlipidemia
Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3
The purpose of this survey is to determine the incidence rate of cardiovascular (CV) events associated with long-term treatment with and without omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in high-risk…
- Trial name
- NCT02285166
- Testing
- Omega-3 fatty acid ethyl esters, Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
- Where
- 2 sites in Japan
- Volunteers
- 15,330 people
- Sponsor
- Takeda
Pulmonary Arterial Hypertension
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH…
- Trial name
- Compass-2 (NCT00303459)
- Testing
- bosentan
- Volunteers
- 334 people
- Sponsor
- Actelion
Obesity
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
- Trial name
- INFORMUS (NCT06098079)
- Testing
- Naltrexone-Bupropion (NB) Combination
- Where
- 140 sites in United States
- Volunteers
- 8,600 people
- Sponsor
- Currax Pharmaceuticals
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
- Trial name
- ACCOMPLISH (NCT00170950)
- Testing
- Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 11,506 people
- Sponsor
- Novartis
Heart Failure, Congestive
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
- Trial name
- NCT00126425
- Testing
- 123I-mIBG (meta-iodobenzylguanidine)
- Where
- United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Atrial Fibrillation
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in patients at high risk of CV events such as patients suffering from nonrheumatic atrial fibrillation.
- Trial name
- SIFA (NCT00244426)
- Testing
- indobufen, aspirin
- Where
- 132 sites in Italy
- Volunteers
- 1,372 people
- Sponsor
- Pfizer
Prevention of Thromboembolic Events, Atrial Fibrillation
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
This is an observational study in which data from people with atrial fibrillation who received or are currently receiving the drug apixaban to prevent thromboembolic events (blood clots that travel through the blood stream to…
- Trial name
- NCT05471830
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in…
- Trial name
- NCT00243178
- Testing
- clopidogrel (SR25990C)
- Where
- 32 sites in United States, Australia and 30 more
- Volunteers
- 6,706 people
- Sponsor
- Sanofi
Carotid Artery Stenosis
Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis
A prospective, multicenter, single-arm, open label clinical study to evaluate the safety and effectiveness of MicroVention, Inc.
- Trial name
- NCT02657707
- Testing
- Roadsaver™ Carotid Artery Stent Device, Nanoparasol® Embolic Protection System
- Where
- 37 sites in United States
- Volunteers
- 295 people
- Sponsor
- Microvention-Terumo, Inc.
Thrombosis, Cancer
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic…
- Conditions
- Thrombosis, Cancer, Pulmonary Embolism
- Trial name
- NCT00320255
- Testing
- Apixaban
- Where
- 14 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Bristol-Myers Squibb
Coronary Disease
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual…
- Trial name
- NCT00621855
- Testing
- dabigatran etexilate
- Where
- 167 sites in United States, Belgium and 22 more
- Volunteers
- 1,878 people
- Sponsor
- Boehringer Ingelheim
Cardiac Arrhythmia
True Continuous ECG Monitoring (TCEM Study)
The purpose of this study is to compare short term (up to 48 hours) traditional cardiac rhythm monitoring using a standard ambulatory Holter monitor versus long term (up to 14 days), continuous ambulatory cardiac rhythm…
- Trial name
- TCEM (NCT01559246)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- iRhythm Technologies, Inc.
Peripheral Arterial Occlusion or Emboli
Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery
The primary objective of this retrospective case review study is to determine the safety and effectiveness of the Penumbra and Indigo Systems for mechanical thrombectomy in a cohort of patients with confirmed peripheral or…
- Trial name
- PRISM (NCT02085551)
- Testing
- Mechanical Thrombectomy by the Indigo System
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Penumbra Inc.
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca